Professional Documents
Culture Documents
Abstract: Solvent-free syntheses of quinazolin-4(3H)-ones were performed by reaction of anthranillic acid with different amides, such as nicotinamide, benzamide, formamide, etc., on montmorillonite K-10. Products were confirmed by
FTIR, 1HNMR, and 13CNMR spectroscopic techniques. All synthesized compounds exhibited antioxidant properties and
have been compared with standard antioxidant BHT.
Key words: quinazolinone, montmorillonite K-10, solvent-free conditions, antioxidant properties.
Rsum : On a ralis des synthses sans solvant de quinazolin-4(3H)-ones par raction de lacide anthranillique avec
divers amides, tel le nicotinamide, le benzamide et le formamide sur de la montmorillonite K-10. Les produits ont t
caractriss par la spectroscopie infrarouge avec transforme de Fourier (IR-TF), et par les mthodes spectroscopiques
de RMN du 1H et du 13C. Tous les produits synthtiss prsentent une proprit antioxydante et ils ont t compars
avec lantioxydant standard, BHT.
Mots-cls : quinazolinone, montmorrillonite K-10, conditions sans solvant, proprits antioxydante
[Traduit par la Rdaction]
Roopan et al.
1025
Introduction
The quinazoline ring skeleton is widely found in alkaloids
and many biologically active compounds. In general, quinazolones were considered important compounds in the fields
of pharmacology and biology (1) because of their wide range
of strong biological activities (26). Some of these compounds are identified as drugs (7) and as diuretics. Among
this class of molecules, quinazolin-4-ones and their derivatives are well-known to possess an array of physiological
activities, e.g., antitubercular (8), antifungal (9), antibacterial
(10), anti-inflammatory, anticancer (11), and anti-proliferative
(5) activities.
Quinazolin-4(3H)-one was prepared by many methods (5,
8, 1013). However, quinazoline derivatives were synthesized mainly by a common approach involving amidation,
starting from anthranilic acid, 2-aminobenzonitrile, and 2aminobenzamide. Other methods included the condensation
of anthranilic acid, ammonium acetate, and the orthoesters
(14), reaction of imidates and anthranilic acid (15), reaction
of polymer-bound isothioureas with isatoic anhydride derivatives (16), and were associated with drawbacks such as
multistep procedures (17), costly reagents, harse reaction
conditions, complex experimental procedures, and low
yields (18). Previous methods have been excluded from
practical applications because of environmental and economic considerations. Finding an efficient method for the
synthesis of quinazolin-4(3H)-one is still a challenge. Nowadays, solvent-free organic reactions have led to experimen-
Experimental
Anthranillic acid and amides used for the reaction were
from Sigma-Aldrich Co., and montmorillonite K-10 was obtained from Fluka. The substances were used as provided
with no other purification. Melting points were taken in
open capillary tubes and are corrected with reference to ben-
Received 17 March 2008. Accepted 29 August 2008. Published on the NRC Research Press Web site at canjchem.nrc.ca on
8 October 2008.
S.M. Roopan, T. Maiyalagan,1 and F.N. Khan.1 School of Science and Humanities, Organic Chemistry Division, VIT University,
Vellore 632 014, Tamil Nadu, India.
1
doi:10.1139/V08-149
1020
Roopan et al.
1021
Table 1 (concluded).
of the reaction, ethyl acetate was added to the reaction mixture, and the catalyst was recovered by filtration. Filtrate
was washed with a 10% NaHCO3 solution to remove any
unreacted acid and further washed with water to remove any
inorganic materials. The organic layer was dried, solvent
evaporated to obtain the products. FT-IR and NMR spectral
techniques were used for product analysis.
1022
Catalyst used
Time (h)
Product 3a
1
2
3
4
5
Silica gel
Bentonite
Montmorillonite KSF
Acidic alumina
Montmorillonite K10
10
10
10
10
10
4
4
4
4
0.5
Nil
Nil
Nil
Low yield
High yield
Amide, R
RCONH2
Montmorillonite
K-10 (g)
Time
(h)
Product 3a
(R)
Yielda
(%)
1
2
3
4
5
6
7
8
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
None
0.02
0.04
0.06
0.08
0.1
0.12
0.14
2
1
1
1
0.5
0.5
0.5
0.5
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
-C5H4N
40
59
67
65
71
85
86
86
Roopan et al.
1023
Cycle No.
Catalyst
amount (g)
Yield
(%)
1
2
3
Cycle I
Cycle II
Cycle III
0.1
0.096
0.091
85
82
81
1024
Fig. 2. Time vs. % inhibition graph for antioxidant property of
quinazolinone derivatives.
2-Pyridin-3-yl-3H-quinazolin-4-one (3a)
Colourless solid, mp 114 C. IR (KBr pellets, cm1) :
3351.67, 1655.03, 1601.16, 1585.32, 1535.27, 1491.45. 1H
NMR (300MHz, CDCl3) : 9.1 (s, 1H), 8.768.75 (d, J =
4.56Hz, 1H), 8.238.20 (d, J = 7.77Hz, 1H), 8.13 (s, 1H),
7.667.64 (d, 1H), 7.467.41 (m, 1H), 7.397.36 (d, J =
7.56, 2H), 7.217.16 (m, 1H). 13C NMR (100 MHz, CDCl3)
: 163.92 (C=O), 152.37, 147.82, 137.49, 135.49, 130.86,
129.17, 125.08, 123.73, 120.51. EI-Mass: 223. GC-MS m/z
223 (M+) C13H9N3O (mol. wt. 223.23) calcd.: C 69.95, H
4.06, N 18.82, O 7.17; found: C 69.83, H 4.14, N 18.75, O
7.01.
2-Phenyl-3H-quinazolin-4-one (3b)
Mp 242246 C (lit. value (32), 242246 C). IR (KBr
pellets, cm1) : 3342.55, 1654.76, 1437.47. 13C NMR
(100MHz, CDCl3) : 165.70 (C=O), 137.85, 134.93, 131.78,
129.03, 128.72, 126.95, 124.51, 120.14. C14H10N2O (mol.
wt. 222.24) calcd.: C 75.66, H 4.54, N 12.60, O 7.20; found:
C 75.54, H 4.46, N 12.52, O 7.11.
2-Methyl-3H-quinazolin-4-one (3c)
Mp 240248 C (lit. value (32), 238240 C). IR (KBr
pellets, cm1) : 3295.81, 1666.07, 1434.67. C9H8N2O (mol.
wt. 160.17) calcd.: C 67.49, H 5.03, N 17.49, O 9.99; found:
C 67.31, H 5.13, N 17.51.
3H-Quinazolin-4-one (3d)
White solid, mp 216 C (lit. value (32), 215216 C). IR
(KBr pellets, cm1) : 3428.88, 1704.98, 1665.87. 13C NMR
(75MHz, CDCl3) : 143.34, 134.89, 127.76, 127.42, 126.35.
C8H6N2O (mol. wt. 146.15) calcd.: C 65.75, H 4.14, N
19.17, O 10.95; found: C 65.80, H 4.03, N 19.04, O 10.86.
(4-Oxo-quinazolin-2yl)-acetonitrile (3e)
Colourless solid, mp 240 C (lit. value (32), 242 C.
C10H7N3O (mol. wt. 185.18) calcd.: C 64.86, H 3.81, N
22.69, O 8.64; found: C 64.74, H 3.91, N 22.57, O, 8.58.
2-(4-Methylphenyl)quinazolin-4(3H)-one (3g)
Colourless solid, mp 240 C (lit. value (31), 239 C). 13C
NMR (75MHz, CDCl3) : 159.9, 147.34, 146.20, 134.31,
133.20, 131.58, 128.15, 127.12, 126.35, 125.14, 124.81,
124.13, 122.11, 19.30. GC-MS m/z 236 (M+).
Supplementary data for this article are available on the journal Web site (canjchem.nrc.ca) or may be purchased from the Depository of
Unpublished Data, Document Delivery, CISTI, National Research Council Canada, Ottawa, ON K1A 0R6, Canada. DUD 3833. For more
information on obtaining material refer to cisti-icist.nrc-cnrc.gc.ca/cms/unpub_e.shtml.
2008 NRC Canada
Roopan et al.
2-(4-Methoxyphenyl)quinazolin-4(3H)-one (3h)
Pale yellow, mp 245247 C (lit. value (31), 244 C). 13C
NMR (75MHz, CDCl3) : 161.22, 148.33, 146.20, 134.32,
133.20, 131.56, 128.11, 127.10, 126.22, 125.14, 124.81,
124.21, 122.13, 19.31. GC-MS m/z 252 (M+).
2-(4-Chlorophenyl)quinazolin-4(3H)-one (3j)
Colourless solid, mp 306308 C (lit. value (31), 312 C).
13
C NMR (75MHz, CDCl3) : 160.12, 147.73, 146.64,
136.45, 135.26, 134.66, 132.62, 130.55, 128.33, 127.91,
126.84, 124.14, 122.43, 19.31. GC-MS m/z 240 (M+).
1H,3H-Quinazolin-2,4-dione (5a)
Pale yellow solid, mp >300 C (lit. value (32) >280 C).
IR (KBr pellets, cm1) : 3367.88 (br), 1673.92, 1609.99.
C8H6N2O2 (mol. wt. 162.15) calcd.: C 59.26, H 3.73, N
17.28, O 19.73; found: C 59.14, H 3.67, N 17.16, O 19.82.
2-Thioxo-2,3-dihydro-1H-quinazolin-4-one (5b)
Colourless solid, mp >300 C. IR (KBr pellets, cm1) :
3406.32, 3203.67, 3008.42, 1696.52, 1263.87. 1H NMR
(400MHz, CDCl3) : 7.89 (s, 1H, NH), 7.457.44 (d, 1H),
7.437.42 (d, 1H), 7.417.37(m, 2H) 7.34 (s, 1H, NH). 13C
NMR (100MHz, CDCl3) : 179.94 (C=S), 137.05, 129.62,
127.15, 125.30. C8H6N2OS (mol. wt. 178.21) calcd.: C
53.92, H 3.39, N 15.72, O 8.98, S 17.99; found: C 53.84, H
3.48, N 15.81, O 8.87, S 17.87.
Conclusion
In conclusion, we have reported a facile synthesis of
quinazolin-4(3H)-ones under solvent-free conditions and
conventional heating, demonstrating the use of montmorillonite K-10 as an efficient, rapid, mild, and inexpensive catalyst. The procedure has the advantages of simplicity and
easy product isolation, coupled with high purity and yields.
Acknowledgement
The authors wish to express their gratitude to Syngene
International Limited for their support of their NMR and
GCMS facilities to carry this research work.
References
1. D.J. Brown. In Comprehensive heterocyclic chemistry. Vol. 3.
Edited by A.R. Katritzky and C.W Rees. Pergamon Press, Oxford, UK. 1984. p. 57.
2. H. Wamhoff and J. Dzenis. Adv. Heterocyclic. Chem. 55, 129
(1992).
3. S. Sinha and M. Srivastava. Prog. Drug Res. 43, 143 (1994).
4. X. Gao, X. Cai, K. Yan, B. Song, L. Gao, and Z. Chen. Molecules, 12, 2621 (2007).
1025
5. S. Yang, Z. Li, L. Jin, B. Song, G. Liu, J. Chen, Z. Chen, D.
Hu, W. Xue, and R. Xu. Bioorg. Med. Chem. Lett. 17, 2193
(2007).
6. J. Bartroli, E. Turmo, M. Alguero, E. Boncompte, M.L.
Vericat, L.Conte, J. Ramis, M. Merlos, J.G. Rafanell, and J.
Forn. J.Med.Chem. 41, 1869 (1998).
7. B.A. Keay and P.W. Dibble. In Comprehensive Heterocyclic
Chemistry. Vol. II. Edited by A.R. Katritzky, C.W. Rees, and
E.F.V. Scriven. Pergamon Press, Oxford, UK. 1996. pp. 395
436.
8. J. Kunes, J. Bazant, M. Pour, K. Waisser, M. Slosarek, and J.
Janota. Il Farmaco, 55, 725 (2000).
9. G. Grover and S.G. Kini. Eur. J. Med. Chem. 41, 256 (2006).
10. A.K. Tiwari, V.K. Singh, A. Bajpai, G. Shukla, S. Singh, and
A.K. Mishra. Eur. J. Med. Chem. 42, 1234 (2007).
11. P.M. Chandrika, T. Yakaiah, A.R.R. Rao, B. Narsaiah, N.C.
Reddy, V. Sridhar, and J.V. Rao. Eur. J. Med. Chem. 43, 846
(2008).
12. D.J. Connolly, D.Cusack, T.P.O. Sullivan, and P.J. Guiry. Tetrahedron, 61, 10153 (2005).
13. G.M. Buckley, N. Davies, H.J. Dyke, P.J. Gilbert, D.R.
Hannah, A.F. Haughan, C.A. Hunt, W.R. Pitt, R.H. Profit, N.C.
Ray, M.D. Richard, A. Sharpe, A.J. Taylor, J.M. Whitworth,
and S.C. Williams. Bioorg. Med. Chem. Lett. 15, 751 (2005).
14. K. Rad-Moghadam and M. Mohseni. J. Chem. Res.
Synop. 487 (2003).
15. W. Ried and W. Stephan. Chem. Ber. 96, 1218 (1963).
16. R.Y. Yang and A. Kaplan. Tetrahedron Lett. 41, 7005 (2000).
17. V. Alagarsamy, S. Murugesan, K. Dhanabal, M. Murugan, and
E. De Clercq. Indian J. Pharm. Sci. 69, 304 (2007).
18. P. Pannerselvam, R.V. Pradeepchandran, and S.K. Sridhar. Indian J. Pharm. Sci. 65, 268 (2003).
19. R.S. Varma. Green Chem. 1, 43 (1999).
20. R.S. Varma. Clean Prod. Pros. 1, 132 (1999).
21. F. Nawaz Khan, R. Jayakumar, and C. N. Pillai. J. Mol. Catal.
A: Chem. 195, 139 (2003).
22. F. Nawaz Khan, R. Jayakumar, and C.N. Pillai. Tetrahedron
Lett. 43, 6807 (2002).
23. V.R. Hathwar, P. Manivel, F. Nawaz Khan, and T.N. Guru
Row. Acta Crystallogr. Sect. E, 63, o3707 (2007).
24. V.R. Hathwar, P. Manivel, F. Nawaz Khan, and T.N. Guru
Row. Acta Crystallogr. Sect. E, 63, o3708 (2007).
25. S. Syed Tajudeen and F. Nawaz Khan. Synth. Commun. 37,
3649 (2007).
26. M.D. Bhor, N.S. Nandurkar, M.J. Bhanushali, and B.M.
Bhanage. Ulrasonics Sonochemistry, 15, 195 (2008).
27. M. Kidwai and R. Mohan. J. Chin. Chem. Soc. 47, 1205 (2006).
28. N.M. Ansari, L. Houlihan, B. Hussain, and A. Pieroni.
Phytother. Res. 19, 907 (2005).
29. H. Chen, M. Zhang, and B. Xie. J. Agric. Food Chem. 52, 11
(2004).
30. C.A. Jaleel, P. Manivannan, B. Sankar, A. Kishorekumar, R.
Gopi, R. Somasundaram, and R. Panneerselvam. Colloids
Surf. B Biointerfaces, 60, 201 (2007).
31. T.Mc.C. Paterson, R.K. Smalley, and H. Suschitzky. Synthesis,
187 (1975).
32. F. Li, Y. Feng, Q. Meng, W. Li, Z. Li, Q. Wang, and F. Tao.
ARKIVOC, i, 40 (2007).